Skip to main content
News Schmidt-Burgk 07.2021
The development team behind the LAMP-Seq method (l-r): Dr. Dr. Ricarda Schmithausen (Institute of Hygiene and Public Health), Prof. Dr. Jonathan Schmid-Burgk (Institute of Clinical Chemistry and Clinical Pharmacology), Dr. Kerstin Ludwig (Institute of Human Genetics) and Dr. Per Hoffmann (Institute of Human Genetics)
© F. Heyder / UKB

Publication

New corona mass test developed by Cluster member

Cluster member Jonathan Schmid-Burgk and colleagues developed a new corona test that is up to 100 times more sensitive than rapid antigen tests.

The "LAMP-Seq" test is based on sequencing technology and can analyze a large number of swabs simultaneously with similar high sensitivity to the commonly used qPCR test. The innovative method offers great potential, especially for systematic testing in day care centers, schools or companies. The results of the study on the new Corona test have been published in the renowned journal "Nature Biotechnology". WDR Lokalzeit from Bonn also reported about this new Corona test and talked to the scientists involved.


Read more in the UKB press release (german)
or watch the TV report from the WDR Lokalzeit (german):

Publication

Kerstin U. Ludwig, Ricarda M. Schmithausen, David Li, Max L. Jacobs, Ronja Hollstein, Katja Blumenstock, Jana Liebing, Mikolaj Slabicki, Amir Ben-Shmuel, Ofir Israeli, Shay Weiss, Thomas S. Ebert, Nir Paran, Wibke Rüdiger, Gero Wilbring, David Feldman, Bärbel Lippke, Nina Ishorst, Lara M. Hochfeld, Eva C. Beins, Ines H. Kaltheuner, Maximilian Schmitz, Aliona Wöhler, Manuel Döhla, Esther Sib, Marius Jentzsch, Jacob D. Borrajo, Jonathan Strecker, Julia Reinhardt, Brian Cleary, Matthias Geyer, Michael Hölzel, Rhiannon Macrae, Markus M. Nöthen, Per Hoffmann, Martin Exner, Aviv Regev, Feng Zhang, Jonathan L. Schmid-Burgk: "LAMP-Seq enables sensitive, multiplexed COVID-19 diagnostics using molecular barcoding", Nature Biotechnology,
https://www.nature.com/articles/s41587-021-00966-9

Related news

Dr. Ivana Jorgacevic und Prof. Dr. Rayk Behrendt have discovered that the inflammatory messenger substance interferon-alpha can trigger Sjögren's syndrome: The researchers in Bonn.

Publication

New test points to precision treatment for autoimmune condition

—Interferon alpha is an inflammatory mediator that can cause Sjögren’s syndrome, an autoimmune disease. This is revealed in a recent study carried out by the University Hospital Bonn together with the University of Bonn, the University of Edinburgh and Newcastle University. Their findings, which have been published in the journal “Lancet Rheumatology,” could make it easier in the medium term to develop drugs to fight this chronic condition.
View entry
Precise Konsortium

Publication Honors & Funding

Making Cancer Cells More Predictable: PRECISE Aims to Forecast Therapeutically Actionable Vulnerabilities

—Which genes and signaling pathways does a cancer cell require to survive? And which of these could serve as therapeutic targets? The pan-European initiative PRECISE aims to identify such vulnerabilities not only through labor-intensive laboratory experiments but also by predicting them using computational models. The UKB and the University of Bonn, represented by Prof. Dr. Maximilian Billmann and Prof. Dr. Jonathan Schmid-Burgk, are among the founding partners of the consortium. The scientific vision of the initiative has now been published in a commentary in Nature Genetics.
View entry
Bild

Publication

Focus on the Guardians of the Antibody Response

—For the immune system to effectively combat pathogens, antibody responses must be precisely controlled. So-called follicular regulatory T cells (Tfr cells) play a key role in this process by limiting excessive immune responses and helping to maintain immune tolerance. Researchers at the University Hospital Bonn (UKB) and the University of Bonn have now developed a robust laboratory method that allows Tfr cells to be generated from precursor cells and studied in a targeted manner. The results were recently published in the journal Cellular & Molecular Immunology.
View entry

Back to the news overview